---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066440"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:16:40.052850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline

## Summary
- Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.
- Received IND clearance from FDA for ALX2004, a novel EGFR-targeted ADC; Phase 1 initiation expected mid-2025 with initial safety data in 1H 2026.
- Will not pursue U.S. registrational path for evorpacept in gastric cancer after FDA feedback that accelerated approval not feasible due to ENHERTU®.
- Discontinued evorpacept in combination with PADCEV® in urothelial cancer due to lack of improved efficacy in ASPEN-07 trial.
- Expect to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies mid-2025, with data milestones in 2026.

## SEC filing metadata
- accession: 0000950170-25-066440
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/0000950170-25-066440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/alxo-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066440
- JSON: https://secwatch.observer/filing/0000950170-25-066440.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.